CV outcomes with a PCSK9 inhibitor: FOURIER studyMar. 16, 2017
ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.
The FOURIER trial was presented during Late-Breaking Clinical Trial Session 1 (March 17), ACC 2017, Washington DC, USA
Recorded at ACC 2017, Washington DC, USA
Faculty & Disclosures
Dr. Marc S. Sabatine, Brigham and Women's Hospital, Boston, USA (Chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group; Lead Author FOURIER study)